The Therasis Filter utilises a systems biology approach to characterise compound mechanism of action, compound-specific biomarkers for clinical development, and synergistic combinations for combination therapy through the construction and analysis of tumor-specific molecular interaction networks.
Millennium chief scientific officer Joseph Bolen said that the Therasis Filter represents an exciting systems biology approach with the potential to streamline the way oncology drugs are developed.
"We believe that understanding the networks of molecular interactions in specific cancer models using systems biology tools may facilitate the early identification of mechanism of action, biomarkers and synergistic drug combinations," Bolen said.